Quick Answer
PMV Pharmaceuticals, Inc. reported R&D Expense of $69.88 million for fiscal year 2025.
PMV Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $69.88M | +19.4% |
| 2024 | $58.53M | +4.7% |
| 2023 | $55.88M | +7.5% |
| 2022 | $51.99M | +42.5% |
| 2021 | $36.49M | +52.5% |
| 2020 | $23.93M | +15.3% |
| 2019 | $20.76M | +49.9% |
| 2018 | $13.85M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.21M | +7.5% | -1.0% |
| June 30, 2025 | $18.40M | +25.8% | +5.5% |
| March 31, 2025 | $17.44M | +32.3% | +2.9% |
| September 30, 2024 | $16.95M | +24.7% | +15.9% |
| June 30, 2024 | $14.63M | +5.7% | +10.9% |
| March 31, 2024 | $13.19M | -12.5% | -2.9% |
| September 30, 2023 | $13.59M | -0.6% | -1.9% |
| June 30, 2023 | $13.84M | +20.8% | -8.2% |
- PMV Pharmaceuticals, Inc. showed an increase of +19.4% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, PMV Pharmaceuticals, Inc.’s r&d expense has grown by 404.4% (from $13.85 million to $69.88 million).
- The most recent figure is from PMV Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: